Pricing
  1. JP-listed companies
  2. ADR120S, Inc.
  3. Financials
  4. Net income

ADR120S, Inc.【JP:3750】

Market cap
¥7.9B
P/E ratio
110.7x
Saitori Cell Research Institute develops regenerative cell therapies and medical devices while also investing in real estate projects through seven subsidiaries.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndNet income (Million JPY)YoY (%)
Mar 31, 2025-2,140-1640.31%
Mar 31, 2024139-113.11%
Mar 31, 2023-1,060+1274.60%
Mar 31, 2022-77-90.06%
Mar 31, 2021-775-342.79%
Mar 31, 2020319-46.11%
Mar 31, 2019593+31.74%
Mar 31, 2018450-196.92%
Mar 31, 2017-464-1460.39%
Mar 31, 201634-71.76%
Mar 31, 2015121-314.26%
Mar 31, 2014-56-23.80%
Mar 31, 2013-74-78.87%
Mar 31, 2012-350

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)